Clinical research site network CenExel Clinical Research announced on Tuesday the appointment of Dr. Sy Pretorius as chief executive officer, effective 1 May 2026.
Dr. Pretorius succeeds Ryan Brooks, who will remain a member of the company's board of directors.
CenExel said that Dr. Pretorius joins the company with more than three decades of experience in clinical research leadership, spanning senior executive and management roles where he was instrumental in driving global clinical development programmes, early-phase research, and integrated clinical trial services.
Dr. Pretorius currently serves as CEO of Ergomed Group, where he leads value creation efforts across the PrimeVigilance, Ergomed CRO and ADAMAS businesses after the group transitioned from the public market to private equity ownership. Prior to joining Ergomed, he served as chief operating officer at EVERSANA, where he led drug and device commercialisation services. Earlier, as president of Clinical Development and chief medical officer at PAREXEL, he oversaw a USD3.6bn global P&L and led more than 16,000 employees worldwide.
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Implantica submits final FDA response for RefluxStop PMA application
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AngioDynamics reports 24-month PRESERVE data showing durable NanoKnife outcomes in prostate cancer
Cepheid receives CE mark for IVDR‑compliant gastrointestinal PCR panel
Abingdon Health supports UK launch of LVOne stroke triage test
Fesarius Therapeutics reports publication of DermiSphere hDRT data
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
Johnson & Johnson secures EU approval for ETHICON 4000 surgical stapler